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Wide ranging experimental evidence suggests that human small-cell lung cancer (SCLC) has a number of molecular and subcellular
characteristics normally associated with neurones. This review outlines and discusses these characteristics in the light of recent
developments in the field. Emphasis is placed upon neuronal cell adhesion molecules, neurone-restrictive silencer factor,
neurotransmitters/peptides and voltage-gated ion, especially Na
þ channels. The hypothesis is put forward that acquisition of such
characteristics and the membrane ‘excitability’ that would follow can accelerate metastatic progression. The clinical potential of the
neuronal characteristics of SCLC, in particular ion channel expression/activity, is discussed in relation to possible novel diagnostic and
therapeutic modalities.
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Small-cell lung cancer (SCLC) has the most aggressive clinical
course of any type of pulmonary tumour, with median survival
time from diagnosis of only months. This is a ‘neuroendocrine’
tumour for which localised forms of treatment, such as surgical
resection or radiation therapy, rarely produce long-term cure, and
cytotoxic chemotherapy remains the main method of treatment. A
remarkable feature of SCLC is that it is the most commonly
encountered form of neoplasm associated with a wide range of
paraneoplastic neurological syndromes (PNSs), including Lam-
bert–Eaton myasthenic syndrome (LEMS), and in more rare cases,
cerebellar degeneration, encephalomyelitis and sensory neuropa-
thy (Honnorat and Cartalat-Carel, 2004). These are a hetero-
geneous group of disorders that are due to secretion of and/or
autoimmune responses to specific molecules produced by the
cancer cells, rather than any direct invasion by tumours. Lambert–
Eaton myasthenic syndrome, which is a form of muscle weakness,
is well understood and is due to the SCLC tumour expressing
voltage-gated Na
þ and/or Ca
2þ channels. In response, the immune
system produces autoantibodies against the channel proteins,
which in turn, can result in suppression of activity at neuromus-
cular junctions (Pancrazio et al, 1989). Such effects can also cause
degeneration of central nervous system (CNS) structures, particu-
larly Purkinje cells, which have very elaborate dendritic trees active
in Ca
2þ signalling. Voltage-gated Na
þ and/or Ca
2þ channels
(VGSCs and VGCCs) are commonly associated with ‘excitable’
cells but also occur in a variety of non-neuronal cell types (e.g. Diss
et al, 2004).
A recent functional ‘neuroscience’ approach that we designed to
elucidate the pathophysiology of human cancer revealed that
membranes of metastatic prostate and breast cancer cells are
potentially ‘excitable’, involving concomitant expression of high
levels of VGSC and reduced levels of voltage-gated K
þ channel
(e.g. Laniado et al, 1997; Fraser et al, 2005). The purpose of this
review is to outline and evaluate the various neuronal aspects of
SCLC, in an integrated approach, with a view ultimately to
questioning their possible functional consequences and clinical
potential.
‘CLASSIC’ MARKERS
A number of antineuronal nuclear antibodies and neurogenetic
markers are well established to be associated with human SCLC.
The term ‘antineuronal nuclear antibody’ (ANNA) was used
originally in relation to the sensory neuropathy syndrome
associated with SCLC. Three main ANNAs have been found,
ANNA-3 being most closely related to SCLC. The ‘neurogenetic
markers’ compromise the four Hu antigen proteins, HuR, HuD,
HuC and Hel-N1 of which HuC, HuD and Hel-N1 are expressed in
neuronal tissues and SCLCs. The Hu antigens have a crucial role in
the development and maintenance of the neuronal phenotype, but
their function(s) in SCLC is unknown. It is possible that anti-Hu
antibodies are part of a complex immune response against Hu
antigens that initially target tumour growth but are misdirected to
cause neurological dysfunction.
Enolases are a group of glycolytic enzymes that exist as dimers
and have broad involvement in mammalian tissue metabolism. Of
the two main isoforms found, one is termed ‘neurone specific
enolase’ (NSE). High concentrations of NSE have been detected
in neuroendocrine cells and neurogenic tumours, as well as in
the blood of SCLC patients. Indeed, NSE is produced by lung
carcinomas and is considered a characteristic tumour-marker in
SCLC. Untreated patients with extensive disease (both lungs
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Aromatic L-amino acid decarboxylase (AADC) is an enzyme of
the lyase class that catalyses the decarboxylation of aromatic
amino acids, converting dopa to dopamine, tryptophan to
tryptamine, and hydroxytryptophan to serotonin. This enzyme is
particularly abundant in brain and other organs such as liver,
kidney and vas deferens. The activity of AADC has been measured
in various normal and tumour cells and tissues and a high level of
mRNA expression and activity were found in SCLC.
Chromogranin A (CgA) has been shown to regulate secretory
granule formation and is coreleased with amines and neuro-
peptides. Detection of CgA in tumour tissue is associated with poor
prognosis. The ubiquitous presence of CgA in ‘neuroendocrine’
cells/tissues makes it a suitable circulating marker for SCLC. It is
not known whether NESP55, a novel Cg-like acidic secretory
protein, that has also been associated with endocrine tumours, also
occurs in SCLC.
NEURONAL CELL ADHESION MOLECULES
Tumour cells generally express numerous cell adhesion molecules
(CAMs), since adhesion, detachment and aggregation play an
important role in tumour invasion and metastasis. Of the two
groups of CAMs that have particularly been well-characterised
(cadherins and Ig superfamily), the neuronal CAM (NCAM),
belonging to the latter, has also been found to be expressed on the
surface of SCLC cells. Neuronal CAMs are encoded by one gene but
three major isoforms are produced by mRNA splicing, giving rise
to proteins of 120, 140 and 180kDa molecular weight. Each NCAM
is extensively modified by post-translational glycosylation; in the
developing embryo, NCAMs have relatively high sialic acid content
(30% by molecular weight vs 10% in the adult) and this results in
lower affinity between NCAMs in their homophilic binding.
Neuronal CAM appears early in embryonic cells and is important
in the formation of cellular assemblies and their boundaries at
sites of morphogenesis. Later in development, NCAM is found on
various differentiated tissues, mediating adhesion among neurones
and between nerve and muscle. Expression of NCAM is highly
indicative of neuroendocrine differentiation and is a potential
tumour marker for SCLC (e.g. Ledermann et al, 1994).
NEURONE-RESTRICTIVE SILENCER FACTOR
The ‘neurone-restrictive silencer factor’ (NRSF), also called ‘REST’,
is a ‘master regulator’, repressing transcription of key neuronal
genes in non-neuronal cells through the ‘neurone-restrictive
silencer element’ (NRSE). The relevant motif occurs in many
‘neuronal’ genes and NRSE has been identified close to the
transcriptional start site of the vasopressin promoter. In SCLC, this
binds multiple NRSF-related complexes that may antagonise the
normal repressor function and thus contribute to the neuro-
endocrine differentiation of SCLC cells. A high level of expression
of a splice variant of NRSF (sNRSF) has been identified in SCLC
(Ledermann et al, 1994). The biological role of NRSF and its
specific expression in SCLC remain to be characterised, but two
main possibilities may be considered. First, NRSF-mediated
transcriptional silencing may be involved in specific expression
of neuropeptides acting as autocrine growth factors in SCLC
(Quinn et al, 2002). Second, NRSF/REST may regulate ion channel
expression. In particular, the VGSC expression/activity, associated
closely with SCLC (Pancrazio et al, 1989; Blandino et al, 1995;
Onganer and Djamgoz, 2005), has been shown to be suppressed by
NRSF/REST (Chong et al, 1995). Importantly, a recent study has
identified REST as a tumour suppressor and has shown that a
defective REST gene can be tumourigenic (Westbrook et al, 2005).
VOLTAGE-GATED ION CHANNELS
Voltage-activated ion channels are a hallmark of neuronal
excitability. In particular, VGSCs are necessary for initiation and
conduction of regenerative potentials and VGCCs are frequently
involved in secretion. Ion channel activity can be controlled by
mitogens and oncogenes, and itself can affect metastatic cell
behaviour, including proliferation. A high level VGSC and VGCC
expression and electrophysiological activity, similar to those in
excitable tissues, have been associated with human SCLC cells
(Pancrazio et al, 1989; Blandino et al, 1995) (Figure 1A and B).
These VGSCs appeared to be a mixture of tetrodotoxin (TTX)-
sensitive and TTX-resistant channels, with a net IC50 of B100nM
(Blandino et al, 1995; Figure 1B and C). However, the functional
role that these channels could play in SCLC behaviour is unknown.
Interestingly, similar upregulation of VGSC expression/activity has
been found in human metastatic prostate cancer in vitro (Laniado
et al, 1997) and in vivo (Diss et al, 2005). Moreover, blockage of
VGSC activity by the highly specific TTX suppressed a variety of
cellular behaviours that would be involved in the metastatic
cascade, including process extension, directional motility (e.g.
Djamgoz et al, 2001), secretory membrane activity (e.g. Krasowska
et al, 2004), adhesion (Mycielska et al, 2004), gene expression (e.g.
Mycielska et al, 2005) and invasiveness in vitro (e.g. Laniado et al,
1997). Emerging data suggest that there is a comparable situation
in metastatic human breast cancer cells (Fraser et al, 2005).
The possible involvement of VGSC activity in metastatic
behaviour of human SCLC cells has recently been investigated by
determining their role in endocytic membrane activity, a measure
of vesicular secretion and plasma membrane protein turnover
(Onganer and Djamgoz, 2005) and proliferation (Onganer et al,
2004). A variety of human SCLC cell lines (H69, H209 and H510)
and a normal human airway epithelial (16HBE14o) cell line were
used. Endocytic uptake of a noncytotoxic tracer, horseradish
peroxidase (HRP) into SCLC cells was vesicular and was inhibited
significantly by TTX, as well as clinically used VGSC drugs,
lidocaine and phenytoin (Figure 1D). These effects were dose
dependent. None of the VGSC blockers used had any effect on
tracer uptake into the 16HBE14o cells (Onganer and Djamgoz,
2005). Treatment with TTX for 24h caused B60% significant
reduction in proliferation of SCLC but only B15% in normal
airway epithelial cells (Onganer et al, 2004). These data would
suggest strongly that VGSC upregulation could enhance metastatic
cell behaviour in SCLC, as shown previously for prostate and
breast cancer. Voltage-gated Na
þ channel protein expression in
human clinical biopsies of SCLC was studied by immunohisto-
chemical staining using a pan-VGSC antibody. There was little or
no VGSC protein expressed in normal human lung tissues (Figure
2C and D). On the other hand, significant upregulation of VGSC
protein was seen in SCLC (Figure 2A and B) (Onganer et al, 2004).
NEUROTRANSMITTERS/PEPTIDES AND RECEPTORS
An increasing number of neuropeptides, including bombesin or
gastrin releasing peptide, bradykinin, vasopressin, galanin, neuro-
tensin, gastrin and cholecystokinin have been implicated in driving
the proliferation of certain SCLC cell lines in an autocrine/
paracrine fashion (reviewed by Seckl and Rozengurt, 1998). These
short regulatory peptides bind to specific cell surface receptors
belonging to the seven-transmembrane domain receptor super-
family. Ligand-bound receptors stimulate heterotrimetric G-
proteins on their intercellular surfaces to elicit downstream
signalling controlling proliferation. Neuropeptides are also known
to modulate VGSCs (e.g. Montano and Djamgoz, 2004). As noted
above, the latter may directly regulate growth or alternatively can
trigger the further secretion of growth factors from SCLC cells.
Stimulation of SCLC growth by acetylcholine or muscarine
(exogenous or endogenous) could be due to Ca
2þ influx mediated
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activation and/or the subsequent opening of VGCCs, triggering
autocrine release of growth factors and/or transcription of growth-
regulatory genes (Song et al, 2003).
Glutamate is the major excitatory neurotransmitter in the
mammalian CNS. A transcriptional gene expression (microarray)
profiling study revealed occurrence of ‘fast-acting’ ionotropic
glutamate receptors (iGluRs) in SCLC cells (Pedersen et al,2 0 0 3 ) .
At present, the role of iGluR expression in SCLC is not known.
During neuronal development, glutamate receptors control prolif-
eration and migration. Glutamate receptor antagonists were found to
inhibit proliferation and motility and increase cell death in lung
carcinomas and a variety of other cancers, and glutamate antagonists
enhanced the effects of cytotoxic drugs (Rzeski et al,2 0 0 2 ) .
CONCLUSIONS AND FUTURE PERSPECTIVES
Liotta and Clair (2000) have commented that ‘y cancer invasion in
general may be a deregulated form of a physiological invasion
process required for neuronal wiring in the embryo, tissue
remodelling of blood vessels, and healing’. The overall conclusion
of the present review is that SCLC has a variety of neuronal
characteristics and that SCLC cells are ‘excitable’. These character-
istics have been studied individually over the years, but clusters of
neuronal/neuroendocrine genes have also been detected by more
recent microarray analyses (Sugita et al, 2002; Pedersen et al, 2003).
Currently, there are two important questions to consider:
First, why should SCLC and other carcinoma, derived from
epithelial cells, acquire such ‘neuronal’ characteristics? In the case
of SCLC, in the first instance, such a strong parallel may not appear
so surprising considering that SCLC cells are derived from
neuroectoderm. More intriguingly, however, this could be due to
neuronal mechanisms being appropriate for membrane ‘excit-
ability’ and hyperactive cell behaviour, hallmarks of metastasis. As
already noted, upregulation of voltage-gated ion channel activity
potentiates a range of cell behaviours integral to the metastatic
cascade (e.g. Mycielska et al, 2004; Fraser et al, 2005; Onganer and
Djamgoz, 2005). There is no doubt that this would be aided
critically by the force of the cells’ membrane potential (equivalent
to some 10
7Vm
 1) and rate of ionic permeation through the
voltage-gated ion channels (B10
5ionsms
 1, in single-file). Inter-
estingly, in SCLC, prognosis was found to be better with LEMS
than without, implying that the VGSC/VGCC autoantibodies may
have some protective effect, consistent with the proposed role of
channel activity in the metastatic cascade (Maddison et al, 1999).
Second, why does the immune system recognise the expression
of at least some of these neuronal antigens as ‘foreign’ and give rise
to PNSs? One possible answer is that such genes are expressed
differently to their normal adult form, possibly due to the de-
differentiated nature of cancer tissue. Importantly, in some
instances, the underlying genes have been found to be ‘embryonic’
splice variants, consistent with the notion of the (re)expression of
oncofeotal genes in cancer (e.g. Monk and Holden, 2001). In fact,
VGSC and NCAM genes expressed in carcinomas were found to be
‘oncofeotal’ (Pedersen et al, 2003; Diss et al, 2005; Fraser et al, 2005).
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Figure 1 Whole-cell patch-clamp recordings from SCLC H146 cells showing expression voltage activated inward (Na
þ) currents. (A) A family of
membrane currents activated at different membrane potentials (values in mV indicated on the right). (B) Current–voltage relationship of voltage-gated Na
þ
currents. Circles – normal data; triangles – effect of 100nM TTX; squares – effect of Na
þ-free medium (choline
þ used as substitute). (C) Dose–response
curve for TTX-induced suppression of the Na
þ current, I (%) expressed as a percentage of the control value. (A–C) Modified from Blandino et al (1995).
(D) Effects of 100nM TTX (1), 200nM lidocaine (2) and 200nM phenytoin (3) on endocytic membrane activity (HRP uptake) into the SCLC cell line, H510
(left-hand sets of histobars) and the normal airway epithelial cell line, 16HBE14o (right-hand sets of histobars). OD540, optical density of HRP content of cell
lysates. Each data set of three histobars shows the effects of the following: HRP uptake (dark), endogenous peroxidase activity (white) and drug (grey) – TTX
(1), lidocaine (2) or phenytoin (3). Each histobar represents the average7s.d. of data from at least six experiments. (D) Modified from Onganer and
Djamgoz (2005).
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with neurons. A particularly interesting mechanism is Hedgehog
signalling, which immediately precedes the neuroendocrine
differentiation in SCLC (Watkins et al, 2003). Hedgehog signalling
also plays a significant role in the patterned growth of CNS.
Another characteristic is expression of neuronal transcription
factors (e.g. POU) in SCLC (Leblond-Francillard et al, 1997).
Generally, SCLC is so aggressive that metastasis would have
occurred by the time it is detected and current therapy methods
(chemotherapy, radiotherapy and surgery) are of limited effect.
Consequently, there is an urgent need to develop new methods for
its clinical management. A final question, therefore, is whether
the neuronal characteristics of SCLC are of diagnostic and/or
therapeutic value. Diagnoses based upon some neuronal char-
acteristics (e.g. NCAM) so far have given mixed results (Chua et al,
2004). As regards possible therapy, a previous attempt targeting
NCAM was also disappointing (Murray et al, 2004). An interesting
future possibility would be to test the diagnostic and therapeutic
potential of functional voltage-gated ion channels (VGSC and/or
VGCC) expressed in SCLC. If these were a common focus of
signalling downstream of multiple growth factors, VGSC/VGCC
expression could be a particularly attractive target, since inhibitors
of individual receptor mechanisms are unlikely to be successful
given the large array of distinct growth factors and receptors
involved in SCLC growth. The indications from cancers of prostate
and breast, as well the data emerging from SCLC (Onganer et al,
2004; Onganer and Djamgoz, 2005) are that the nature of the VGSC
expression/involvement in metastatic cell behaviour is so as to
make it an early, functional marker of metastatic disease.
Furthermore, since TTX or anticonvulsant drugs inhibit metastatic
cell behaviour, VGSCs could represent a novel target for
suppressing SCLC.
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